TrialAnnals of the rheumatic diseases2019

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.

Tsutomu Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.